Steven Gullans is the new president and CEO of RxGen, the company said this week. He will replace Harry Penner, the interim CEO, who will remain chairman of the board. Gullans, a co-founder of RxGen, joins the company from US Genomics, where he was CSO. He holds a PhD in physiology from Duke University and a BS from Union College.
Robert Millman has become chief patent counsel of Alnylam Pharmaceuticals, the Cambridge, Mass.-based company said on Monday. He has been a company consultant since 2003. Most recently, Millman was a freelance intellectual property consultant for biotechnology companies and the interim chief patent counsel at Infinity Pharmaceuticals. Prior to that, he was chief IP counsel at Celera Genomics. Millman holds a JD degree from the Washington College of Law at American University. He also holds an MS in genetics from Washington State University and a BS in biochemistry from the University of California, Riverside.
Lars Holmkvist has become president of Applied Biosystems Europe, ABI said on Monday. Most recently, he was vice president of vascular and cardiac surgery in Western Europe for Medtronic.
Mehis Pold has become director of research in molecular medicine at CeMines, the Evergreen, Colo.-based company said last week. Since 2000, he has been a researcher in the division of pulmonology at the University of California, Los Angeles.